Physician profile
Lijo John
NPI 1295050037
$4,731.19
in general payments reported to CMS, 2019-2025
38 companies · $542 in 2025
The $542 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.11 · 2021: $134 · 2022: $136 · 2023: $3,455 · 2024: $399 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,678 · Food and Beverage: $1,520 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,677.50 |
| Food and Beverage | $1,520.22 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,779.18 | 2022-2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $199.69 | 2021-2025 | Ojjaara, Shingrix |
| Novartis Pharmaceuticals Corporation | $148.85 | 2022-2025 | |
| Janssen Biotech, INC. | $144.42 | 2022-2023 | Darzalex |
| Abbvie INC. | $141.70 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $135.21 | 2022-2025 | Imjudo, Imfinzi, Calquence |
| Pharmacyclics LLC, An Abbvie Company | $134.90 | 2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $134.51 | 2021-2025 | Opdivo |
| Myriad Genetic Laboratories, INC. | $100.05 | 2023 | Myrisk |
| Pfizer INC. | $88.19 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.38 | 2023 | |
| Daiichi Sankyo INC. | $65.49 | 2023-2025 | Enhertu |
| Emd Serono, INC. | $58.33 | 2023 | Bavencio |
| Celgene Corporation | $55.01 | 2023-2025 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $45.08 | 2023-2025 | Vyloy, Xospata |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $44.60 | 2019 | |
| Abiomed | $40.54 | 2025 | |
| Lilly USA, LLC | $34.83 | 2023-2024 | Verzenio, Jaypirca |
| Seagen INC. | $32.49 | 2023 | Padcev |
| Boston Scientific Corporation | $26.22 | 2025 | Peripheral Rotawire and Wireclip Torquer |
| Incyte Corporation | $25.00 | 2024 | Monjuvi |
| Genzyme Corporation | $24.26 | 2023 | |
| Pharmaessentia USA Corporation | $22.70 | 2025 | Besremi |
| Eisai INC. | $22.53 | 2025 | |
| Amgen INC. | $19.51 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.46 | 2025 | |
| Array Biopharma INC | $19.43 | 2025 | Mektovi, Lorbrena, Braftovi |
| Morphosys, US INC. | $18.02 | 2022 | |
| Cti Biopharma Corp. | $17.39 | 2023 | Vonjo |
| Merck Sharp & Dohme LLC | $15.02 | 2025 | Keytruda, Welireg, Lynparza |
| Sun Pharmaceutical Industries INC. | $14.87 | 2023 | Odomzo, Yonsa |
| Exelixis INC. | $14.41 | 2025 | Cabometyx |
| Gilead Sciences, INC. | $11.92 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lijo John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.